Current Studies

The facts about participating in clinical research and our ongoing studies:

First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.

Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.

For more information, please call: 954-366-0277.

 

CURRENTLY ENROLLING CLINICAL TRIALS

HOLLYWOOD NEUROLOGY
To participate or refer a patient, call 954-366-0277; Ext 120 – Jorge, Ext 121 – Rebecca, Ext 124 – Lucy, Ext 122 – Muskaan

Clinical Coordinators: Jorge Riveros, IMG, CCRC • Rebecca Nembhard, CCRC • Lucy Vargas, MA, CRC • Muskaan Ochani, BS, CRC

Sage: Alzheimer’s Disease/Memory loss – Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants with Mild Cognitive Impairment or Mild Dementia Due to Alzheimer’s Disease ages 50-80

Axsome: Migraine – An open label, multidose evaluation of the efficacy and safety of AXS-07 (Meloxican and Rizatriptan) for the Acute treatment of Migraine in adult with an inadequate response to oral CGRP inhibitors. Patients over 18 years of age.

Axsome: Alzheimer’s with Agitation ADVANCE-2 – A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Alzheimer’s Disease Agitation for 6 weeks, followed by an Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects with Dementia of the Alzheimer’s Type ages 65-90.

Ipsen Chronic Migraine – A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants 18 years or older.

Ipsen Episodic Migraine – Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants 18 years or older.

Lexicon: Diabetic Peripheral Neuropathy – Phase 2b Randomized, Double blind Placebo controlled Parallel Group, Multicenter study in Patients with Diabetic Peripheral Neuropathy Pain (PROGRESS)
In patients 18 or older with a diagnosis of T1DM or T2DM with DPNP.